news
Early allogeneic cell therapy trial results offer hope for sight condition
Based on positive outcomes of the clinical trial, a high dose of the cell therapy is expected to advance to Phase III pivotal trials.
List view / Grid view
Inc.
article
Alzheimer’s drug development roundup – July 2024
From exciting data on cell therapy and monoclonal antibodies, through to new regulatory developments, this article summarises some of the key developments within the Alzheimer’s therapeutic landscape over July.
article
QA/QC Microbiology In-Depth Focus 2024
This in-depth focus features articles on single temperature incubation, endotoxin standards and aseptic connections in pharmaceutical manufacturing.
news
Biologics driving continuous bioprocessing market expansion
Research predicts the global continuous bioprocessing market will witness a CAGR of 19.72 percent between 2024-2031.
news
New acquisition to support global gene therapy manufacturing
Acquisition of Forge Biologics by Ajinomoto Co., Inc. is set to extend global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc.
news
Biotechnology/pharmaceutical services outsourcing market worth $92.9bn by 2025
The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025, according to a report by Grand View Research, Inc...
news
First-in-Human trial of cannabis-based therapy for Parkinson’s initiated
GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies...
news
FDA approves tests to screen for tickborne parasite in whole blood and plasma
The FDA has approved tests intended to be used as donor screening tests on samples from individual human donors, including volunteer donors of whole blood and blood components...
news
FDA approves Glatopa a generic option for relapsing forms of multiple sclerosis
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
news
Biktarvy approved for the treatment of HIV-1 infection
The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection...
news
FDA approves lynparza for breast cancer with BRCA gene mutation
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
news
Ogivri approved as the first biosimilar against certain breast and stomach cancers
The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene...
news
US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
news
Sucampo announces publication of NICE recommendation for AMITIZA® (Lubiprostone)
23 July 2014 | By Sucampo Pharmaceuticals, Inc
Sucampo Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone)...
news
Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone for metastatic castrate-resistant prostate cancer
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
